Early patient access single named patient program for the use of ulocuplumab for the treatment of multiple myeloma


Participant that has been diagnosed with Relapsed/ Refractory Multiple Myeloma and are currently participating in a clinical trial which is closing. This research study is studying Ulocuplumab as a possible treatment. It's an expanded access from NCT01359657

Study Start Date

Not specified

Estimated Completion Date

Not specified


  • Drug: Dexamethasone
  • Drug: Lenalidomide
  • Drug: Ulocuplumab
  • Drug: Bortezomib


  • Internal Medicine: Hematology/Oncology,Neurology
  • Oncology: Leukemia/Lymphoma,Soft Tissue/Sarcoma

MeSH Terms

  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Study ID

Dana-Farber Cancer Institute -- 16-002



Trial ID


Study Type

Expanded Access

Trial Phase


Enrollment Quota

Not Listed


Dana-Farber Cancer Institute

Inclusion Criteria

  • Signed informed consent document
  • Must be currently participating on protocol 11-240 (DFCI)/ CA 212-002(BMS), tolerating therapy, and still receiving benefit from treatment.

Exclusion Criteria

  • Prior exposure to Ulocuplumab other than in DFCI Protocol 11-240 (BMS protocol CA212-002) or any other any other CXCR4 inhibitor (small molecule within 14 days
  • antibody against CXCR4 within 10 weeks).




18 Years and older

Accepts Healthy Volunteers

Not Listed

Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Dana Farber Cancer Institute - Boston, Massachusetts 2.4 miles Irene M Ghobrial MD 617-632-4198 Irene_Ghobrial@dfci.harvard.edu

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.